What is the effect of hormone replacement therapy (HRT) on melanoma risk in women, especially those with a personal or family history of melanoma?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: June 19, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

HRT Does Not Increase Melanoma Risk or Worsen Prognosis

Hormone replacement therapy (HRT) does not increase the risk of developing melanoma and does not worsen prognosis in women with existing melanoma, including those with personal or family history of the disease. Decisions about HRT use should be made based on other health considerations, not melanoma concerns 1.

Evidence from Clinical Guidelines

The 2010 UK Guidelines for Management of Cutaneous Melanoma provide the clearest guidance on this issue, stating explicitly:

  • No increased risk of melanoma with HRT use
  • No worsening of prognosis in stage I and II melanoma (Level IIa evidence)
  • Decisions about HRT should be made on the basis of health issues other than melanoma 1

This represents consensus from dermatology and melanoma specialists based on observational evidence, and these recommendations have remained consistent across guideline updates.

Reconciling Conflicting Research Evidence

While guidelines are clear, recent research shows mixed findings that require careful interpretation:

Studies suggesting increased risk:

  • A 2023 meta-analysis found HRT associated with modest increased melanoma risk (HR 1.11,95% CI 1.05-1.19), particularly with estrogen monotherapy and use >5 years 2
  • A 2025 meta-analysis showed similar findings (OR 1.18 for HRT and melanoma) 3
  • A Norwegian cohort found estrogen therapy increased risk (RR 1.45), but progestins appeared protective (RR 0.71 per 10 mg/month) 4

Studies showing no increased risk:

  • A Danish population study of 8,279 melanoma cases found associations were strongest for recent users, localized disease, and intravaginal estrogens—suggesting detection bias rather than causation, with no dose-response relationship 5
  • A Taiwanese cohort of 14,291 HRT users found no significant melanoma risk (95% CI 0.386-1.099) 6

Critical Analysis: Why Guidelines Remain Reassuring

The guideline position is justified despite some positive research associations because:

  1. Lack of biological plausibility: The associations are weak, inconsistent, and lack clear dose-response relationships
  2. Detection bias: Stronger associations with recent use, localized disease, and among women with higher healthcare utilization suggest increased surveillance rather than true causation 5
  3. No impact on survival: HRT does not worsen melanoma prognosis or survival outcomes 1, 5
  4. Conflicting hormone effects: Estrogens may increase risk while progestins decrease it, suggesting complex non-causal relationships 4

Clinical Recommendations by Patient Scenario

For women without melanoma history:

  • HRT can be prescribed based on standard menopausal indications
  • Melanoma risk should not factor into the decision
  • Ensure appropriate skin cancer screening regardless of HRT use

For women with prior melanoma (Stage I-II):

  • HRT is not contraindicated based on melanoma history alone 1
  • Prognosis is not worsened by HRT use
  • Decision should focus on menopausal symptoms, cardiovascular health, bone density, and breast cancer risk
  • Continue routine melanoma surveillance as indicated by stage

For women with family history of melanoma:

  • Family history alone does not contraindicate HRT
  • Focus on established melanoma risk reduction: sun protection, skin self-examination, regular dermatologic surveillance
  • HRT decisions should be based on standard menopausal therapy considerations

For women with advanced melanoma (Stage III-IV):

  • Guidelines do not specifically address this population
  • Individual discussion warranted given limited data
  • Consider quality of life benefits of HRT for severe menopausal symptoms
  • No evidence HRT worsens outcomes even in advanced disease

Important Caveats

  • Breast cancer history remains the primary contraindication to systemic HRT, not melanoma history
  • Women using HRT should maintain appropriate skin cancer screening based on their individual risk factors (sun exposure, skin type, number of moles)
  • Vaginal estrogen preparations show similar lack of melanoma risk as systemic preparations 1, 5
  • The weak associations in some studies may reflect confounding by sun exposure and healthcare-seeking behavior rather than true causation

Bottom Line for Practice

Do not withhold HRT from women based on melanoma concerns—either for prevention or in those with melanoma history. The guideline consensus, supported by the most rigorous population studies showing no survival impact, should guide clinical practice over meta-analyses that may be confounded by detection bias 1, 5. Focus HRT decisions on established indications and contraindications (particularly breast cancer), not melanoma.

References

Related Questions

What is the risk of melanoma recurrence in a patient with a prior melanoma who receives systemic hormone therapy (e.g., estrogen-containing regimens)?
What causes a melanoma to appear red?
What are the differential diagnoses for a lesion that could be melanoma and how should it be evaluated?
Describe melanoma.
Is the presence of hair on a mole a sign of melanoma?
What laboratory tests should be obtained for a newborn of a mother taking levothyroxine (Synthroid)?
Should hydroxyurea be initiated or continued during an acute sickle cell pain crisis?
How should subclinical hypothyroidism (elevated thyroid stimulating hormone with normal free thyroxine and free triiodothyronine) be managed, and is tirzepatide appropriate for weight loss or diabetes in this setting?
What is the appropriate intravenous infusion rate for levofloxacin (Levaquin) 500 mg?
What is the normal aldosterone-to-renin activity ratio (ARR) value?
What is the recommended dosage of Penicillin V (Penicillin V) for adults?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.